Skip to main content
Skip to main content
Our Company
Who We Are
Our Team
Our Science
Our Approach
Role of Progranulin
Pipeline
Overview
Frontotemporal Dementia
Patients and Caregivers
Our Commitment
Compassionate Use Statement
Community Resources
Investors and News
Overview
News
Events and Presentations
Financials and Filings
Stock Information
Investor FAQs
Resources
Corporate Governance
Inquiries and Alerts
Careers
Contact
Toggle Site Search
Search query
Search query
Our Company
Who We Are
Our Team
Our Science
Our Approach
Role of Progranulin
Pipeline
Overview
Frontotemporal Dementia
Patients and Caregivers
Our Commitment
Compassionate Use Statement
Community Resources
Investors and News
Overview
News
Events and Presentations
Financials and Filings
Stock Information
Investor FAQs
Resources
Corporate Governance
Inquiries and Alerts
Careers
Contact
Events and Presentations
Event Details
ESGCT Poster: Interim Safety and Biomarker Data From upliFT-D Trial of PBFT02, an AAV Gene Therapy for FTD with GRN Mutations
October 9, 2025
08:00 AM ET
ESGCT Poster Oct 2025
(opens in new window)
PDF
289 KB
Read the latest news about Passage Bio